Repligen Corporation (NASDAQ:RGEN) shares, rose in value on Friday, 05/13/22, with the stock price up by 4.39% to the previous day’s close as strong demand from buyers drove the stock to $150.40.
Actively observing the price movement in the last trading, the stock closed the session at $144.07, falling within a range of $146.32 and $152.005. The value of beta (5-year monthly) was 0.91 whereas the PE ratio was 59.59 over 12-month period. Referring to stock’s 52-week performance, its high was $327.32, and the low was $137.21. On the whole, RGEN has fluctuated by -6.09% over the past month.
With the market capitalization of Repligen Corporation currently standing at about $8.42 billion, investors are eagerly awaiting this quarter’s results, scheduled for May 02, 2022 – May 06, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be $0.65, which is expected to increase to $0.81 for fiscal year $2.82 and then to about $3.13 by fiscal year 2022. Data indicates that the EPS growth is expected to be 70.90% in 2022, while the next year’s EPS growth is forecast to be 11.00%.
Analysts have estimated the company’s revenue for the quarter at $179.29 million, with a low estimate of $175.78 million and a high estimate of $181.56 million. According to the average forecast, sales growth in current quarter could jump up 65.00%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2022, the company’s y-o-y revenues would reach $664.38 million, representing an increase of 81.40% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that RGEN’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
9 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 1 analyst(s), 8 recommend it as a Buy and 0 called the RGEN stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Buy.
The stock’s technical analysis shows that the PEG ratio is about 1.99, with the price of RGEN currently trading nearly -1.76% and -10.14% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 44.43, while the 7-day volatility ratio is showing 6.04% which for the 30-day chart, stands at 6.26%. Furthermore, Repligen Corporation (RGEN)’s beta value is 0.98, and its average true range (ATR) is 9.60.
A comparison of Repligen Corporation (RGEN) with its peers suggests the former has fared considerably weaker in the market. RGEN showed an intraday change of 4.39% in last session, and over the past year, it shrunk by -12.54%%. In comparison, Thermo Fisher Scientific Inc. (TMO) has moved higher at 2.97% on the day and was up 17.94% over the past 12 months. On the other hand, the price of Danaher Corporation (DHR) has risen 4.02% on the day. The stock, however, is off -1.73% from where it was a year ago. Additionally, there is a gain of 2.42% for General Electric Company (GE) in last trading while the stock has seen an overall depriciation of -29.25%% over the past year. The PE ratio stands at 59.59 for Repligen Corporation, compared to 28.21 for Thermo Fisher Scientific Inc., and 29.25 for Danaher Corporation. Other than that, the overall performance of the S&P 500 during the last trading session shows that it gained 2.39%. Meanwhile, the Dow Jones Industrial Improved by 1.47%.
Data on historical trading for Repligen Corporation (NASDAQ:RGEN) indicates that the trading volumes over the past 10 days have averaged 0.63 million and over the past 3 months, they’ve averaged 534.48K. According to company’s latest data on outstanding shares, there are 55.35 million shares outstanding.
Nearly 0.70% of Repligen Corporation’s shares belong to company insiders and institutional investors own 86.30% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 2.13 million shares as on Feb 14, 2022, resulting in a short ratio of 5.41. According to the data, the short interest in Repligen Corporation (RGEN) stood at 3.86% of shares outstanding as of Feb 14, 2022; the number of short shares registered in Jan 13, 2022 reached 1.61 million. The stock has fallen by -43.21% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the RGEN stock heading into the next quarter.